SimBioSys, a clinical AI company leveraging spatial biophysics to drive precision in breast cancer treatment, and Ricoh 3D for Healthcare, LLC, a wholly owned subsidiary of Ricoh USA, Inc. (Ricoh) focused on delivering FDA-cleared, patient-specific medical devices through centralised and point-of-care manufacturing,  announced a strategic, non-exclusive distribution agreement to broaden market access to TumorSight Viz—SimBioSys' FDA-cleared 3D surgical visualisation platform for breast cancer.

TumorSight Viz converts standard breast MRI into intuitive, 3D visualisations that reveal tumour size, location, and spatial orientation relative to surrounding anatomy—supporting more informed and individualised surgical decision-making. TumorSight Viz 1.3 offers industry-leading segmentation accuracy, delivers case results in minutes, and integrates with hospital PACS to streamline planning and coordination.1

This partnership follows the recent FDA 510(k) clearance of TumorSight Viz 1.3 and reflects a shared commitment to bringing next-generation digital health technologies to market at scale. By combining SimBioSys' category-defining software with Ricoh's deep expertise in healthcare services, surgical oncology clinician relationships, and nationwide reach, the companies aim to accelerate the adoption of AI-powered surgical visualisation tools in breast cancer care.

"At SimBioSys, we're focused on delivering innovation that empowers clinicians to make more precise, personalised surgical decisions," said Stacey Stevens, President and CEO, SimBioSys. "Ricoh's reach, reputation, and commitment to advancing surgical innovation make them an ideal partner to help bring TumorSight Viz to more clinical teams and patients. This partnership enables us to meet the increasing demand for tools that help improve outcomes, reduce variability, and elevate the surgical experience for both providers and patients."